---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-131074"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T18:15:21.475311+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kyverna CMO James Chung resigns; receives $220K severance and COBRA

## Summary
- CMO James Chung's employment terminated effective November 22, 2024.
- Severance of $220,000 (6 months base salary) plus COBRA premiums for up to 6 months.
- Stock options cease vesting as of Separation Date; release of claims signed.
- No replacement named; Company expresses best wishes in future endeavors.

## SEC filing metadata
- accession: 0000950170-24-131074
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017024131074/0000950170-24-131074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017024131074/kytx-20241126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-131074
- JSON: https://secwatch.observer/filing/0000950170-24-131074.json
- Plain text: https://secwatch.observer/filing/0000950170-24-131074.txt

## Key facts
- Executive change
  James Chung resigned as Chief Medical Officer at Kyverna Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: As previously disclosed, James Chung, M.D., Ph.D., Chief Medical Officer of Kyverna Therapeutics, Inc. (the “Company”), resigned from the Company, to be effective as of November 22, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000095017024131074/0000950170-24-131074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.